Sequencing by synthesis (SBS) has been a successful commercially-viable method to obtain large quantities of DNA sequencing data. SBS involves binding of primer-hybridized template DNA, incorporation of a deoxynucleoside triphosphate (dNTP), and detection of incorporated dNTP.
Current sequencing systems use fluorescence signal detection. Four fluorescently-labeled nucleotides are used to sequence millions of clusters in parallel. DNA polymerase catalyzes the incorporation of fluorescently-labeled dNTPs into a DNA template strand during sequential cycles of DNA synthesis. During each cycle, a single labeled dNTP is added to the nucleic acid chain. The nucleotide label serves as a “reversible terminator” for polymerization. After the dNTP has been incorporated, the fluorescent dye is identified through laser excitation and imaging, then enzymatically cleaved to allow the next round of incorporation. The base is identified directly from signal intensity measurements during each cycle.
State-of-the-art sequencing systems that rely on fluorescence signal detection can provide throughputs of up to 20 billion reads per run. Achieving such performance, however, requires large-area flow cells, high-precision free-space imaging optics, and expensive high-power lasers to generate sufficient fluorescence signals to enable successful base detection.
Two general strategies have enabled a gradual increase in SBS throughput (e.g., characterized by base reads per run). The first approach has been outward scaling, by increasing the size and the number of flow-cells in the sequencers. This approach increases both the cost of reagents and the price of the sequencing system, because it requires additional high-power lasers and high-precision nano-positioners.
The second approach involves inward scaling, where the size of individual DNA testing sites is reduced so that the number of sequenced DNA strands in a fixed-size flow-cell is higher. This second approach is more appealing to reduce the overall sequencing cost because additional cost only involves implementation of better imaging optics while keeping the cost of consumables the same. But higher numerical aperture (NA) lenses must be employed to distinguish the signal from neighboring fluorophores. This approach has limits because the Rayleigh criterion puts the distance between resolvable light point sources at 0.61 λ/NA, i.e., even in advanced optical imaging systems, the minimum distance between two sequenced DNA strands cannot be reduced beyond approximately 400 nm. Similar resolution limits apply to sequencing directly on top of imaging arrays where the smallest pixel size achieved so far is less than 1 μm. The Rayleigh criterion currently represents the fundamental limitation for inward scaling of optical SBS systems. Overcoming these limitations may require super-resolution imaging techniques, which has not yet been achieved in highly multiplexed systems. Hence, at this stage, the only practicable way to increase the throughput of optical SBS sequencers is to build bigger flow-cells and more expensive optical scanning and imaging systems.
Thus, there is a need to improve SBS.
Objects, features, and advantages of the disclosure will be readily apparent from the following description of certain embodiments taken in conjunction with the accompanying drawings in which:
To facilitate understanding, identical reference numerals have been used, where possible, to designate identical elements that are common to the figures. It is contemplated that elements disclosed in one embodiment may be beneficially utilized in other embodiments without specific recitation. Moreover, the description of an element in the context of one drawing is applicable to other drawings illustrating that element.
Disclosed herein are apparatuses for nucleic acid sequencing using magnetic labels (e.g., magnetic particles) and magnetic sensors. Also disclosed are methods of making and using such apparatuses. For simplicity, some of the discussions below refer to sequencing DNA as an example. It is to be understood that the disclosures herein apply generally to nucleic acid sequencing.
The inventors recognized that the resolution limits of fluorescence microscopy and CMOS imagers, as used in prior art SBS, do not apply to electric charge (e.g., silicon nanowire field-effect transistors (FETs)) or magnetic field sensors (e.g., spin valves, magnetic tunnel junctions (MTJs), spin-torque oscillators (STOs), etc.), where the size of sensing elements is an order of magnitude smaller and the level of multiplexing considerably higher than in state-of-the-art SBS systems. Magnetic field sensing in SBS is particularly appealing because DNA and sequencing reagents are non-magnetic, which enables significant improvements to signal-to-noise ratio (SNR) compared to electric charge sensing schemes based on electron transport modulation in CMOS components. Furthermore, magnetic sensing does not require the incorporated bases to be in direct contact with the junction. Miniaturized magnetic field sensors can be used to detect nanoscale magnetic nanoparticles to perform SBS.
Performing SBS using magnetic sensor arrays can dramatically increase the throughput and reduce the cost of sequencing by providing additional inward scaling by a factor of, for example, approximately 100 while eliminating the need for high-power lasers and high-resolution optics in sequencing systems.
This document discloses SBS protocols that use magnetically-labeled nucleotide precursors in conjunction with sequencing devices that include arrays of magnetic sensing elements (e.g., MTJs, STOs, spin valves, etc.). The devices also include one or more etched binding areas that allow the magnetic sensors to detect the magnetic labels in the magnetically-labeled nucleotide precursors while protecting the magnetic sensors from damage (e.g., using a thin layer of insulator).
Among the disclosures herein is the disclosure of an apparatus for nucleic acid sequencing, the apparatus comprising a plurality of magnetic sensors, a plurality of binding areas disposed above the plurality of magnetic sensors, each of the binding areas for holding fluid, and at least one line for detecting a characteristic of at least a first magnetic sensor of the plurality of magnetic sensors, the characteristic indicating presence or absence of one or more magnetic nanoparticles coupled to a first binding area associated with the first magnetic sensor. In some embodiments, the first magnetic sensor comprises a magnetoresistive (MR) device. The MR device may comprise a pinned layer, a free layer, and a barrier layer disposed between the pinned layer and the free layer. In some such embodiments, in the absence of the one or more magnetic nanoparticles coupled to the first binding area, a magnetic moment of the pinned layer is approximately 90 degrees from a magnetic moment of the free layer.
The first binding area may include a structure (e.g., a cavity or ridge) configured to anchor nucleic acid to the first binding area.
In some embodiments, the shape of the first magnetic sensor is substantially cylindrical or substantially cuboid. In some embodiments, a lateral dimension of the first magnetic sensor is between approximately 10 nanometer (nm) and approximately 1 micrometer.
The apparatus may also include sensing circuitry coupled to the plurality of magnetic sensors via the at least one line. The sensing circuitry may be configured to apply a current to the at least one line to detect the characteristic (e.g., a magnetic field, a resistance, a change in magnetic field, a change in resistance, a noise level, etc.) of the first magnetic sensor. In some embodiments, the sensing circuitry comprises a magnetic oscillator, and the characteristic is a frequency of a signal associated with or generated by the magnetic oscillator.
The apparatus may have an insulating material (e.g., an oxide (e.g., silicon dioxide, aluminum oxide, etc.), a nitride (e.g., silicon nitride, etc.)) disposed between the plurality of magnetic sensors and the plurality of binding areas. The thickness of the insulating material between a top of the first magnetic sensor and the first binding area may be, for example, between approximately 3 nm and approximately 20 nm.
In some embodiments, the at least one line includes a first line disposed above a top surface of the first magnetic sensor, and the first binding area is located within a trench in the first line, the trench being above the top surface of the first magnetic sensor.
In some embodiments, the plurality of magnetic sensors is arranged in a rectangular array, and the at least one line includes at least a first line and a second line, the first line being disposed above the first magnetic sensor and the second line being disposed below the first magnetic sensor. One or more binding areas may be located within trenches in the first line. In some embodiments, the first line is coupled to a row of the rectangular array and the second line is coupled to a column of the rectangular array, or vice versa.
Also disclosed herein are methods of manufacturing apparatuses for nucleic acid sequencing. In some embodiments, a method of manufacturing a nucleic acid sequencing device comprises fabricating a first line, fabricating a plurality of magnetic sensors, depositing insulating material between the magnetic sensors, fabricating a plurality of additional lines, and creating a plurality of binding areas. In some embodiments, each magnetic sensor's bottom surface is coupled to the first line, and each magnetic sensor's top surface is coupled to a respective one of the additional lines.
Fabricating the first line may comprise depositing a metal layer on a substrate (e.g., using physical vapor deposition, ion beam deposition, etc.), and patterning the metal layer into the first line (e.g., using photolithography, milling, and/or etching).
In some embodiments, after fabricating the first line and before fabricating the plurality of magnetic sensors, insulating material is deposited over the first line, the first line is then uncovered (e.g., using chemical mechanical polishing (CMP)), and the plurality of magnetic sensors is fabricated on the uncovered first line.
The plurality of magnetic sensors may be fabricated by depositing a plurality of layers on the first line, and patterning the plurality of layers (e.g., using photolithography and/or etching) to form the plurality of magnetic sensors, each of the plurality of magnetic sensors having a predetermined shape (e.g., substantially cylindrical, substantially cuboid, etc.). Depositing the plurality of layers may comprise depositing a first ferromagnetic layer, depositing a metal or insulator layer over the first ferromagnetic layer, and depositing a second ferromagnetic layer over the metal or insulator layer. A lateral dimension of each of the plurality of magnetic sensors may be, for example, between approximately 10 nm and approximately 1 micrometer.
In some embodiments, the plurality of magnetic sensors is in a rectangular array, and the first line corresponds to a row of the rectangular array, and each of the plurality of additional lines corresponds to a column of the rectangular array, or vice versa.
In some embodiments, after depositing the insulating material between the magnetic sensors and before fabricating the plurality of additional lines, a chemical mechanical polishing step is performed to expose the top surface of each of the plurality of magnetic sensors.
In some embodiments, fabricating the plurality of additional lines comprises depositing a layer of metal, performing photolithography to define the plurality of additional lines, and removing a portion of the layer of metal.
In some embodiments, creating the plurality of binding areas comprises applying a mask over the plurality of binding areas, depositing (e.g., using atomic layer deposition) a metal layer over the mask, and lifting the mask. Additional insulating material (e.g., an oxide (such as silicon dioxide, etc.) or nitride between approximately 3 nm and approximately 20 nm thick) may then be deposited over the plurality of additional lines and the plurality of binding areas after lifting the mask.
Also disclosed herein are methods of sequencing nucleic acid using the disclosed nucleic acid sequencing apparatuses. In some embodiments, a method comprises (a) binding at least one nucleic acid strand to the first binding area, (b) in one or more rounds of addition, adding, to the first binding area, an extendable primer and nucleic acid polymerase, (c) adding, to the first binding area, a first nucleotide precursor, the first nucleotide precursor labeled by a first cleavable magnetic label, and (d) sequencing the nucleic acid strand. The first cleavable magnetic label may comprise a magnetic nanoparticle (e.g., a molecule, a superparamagnetic nanoparticle, a ferromagnetic nanoparticle, etc.). The first binding area may be washed before step (c). Additional molecules of the nucleic acid polymerase may be added to the first binding area after step (c). Steps (c) and (d) may be repeated with a different nucleotide precursor during each repetition, each of the different nucleotide precursors being magnetically labeled. The first nucleotide precursor may comprise one of dATP, dGTP, dCTP, dTTP, or equivalents. Each of the first and different nucleotide precursors may be selected from magnetically-labeled adenine, guanine, cytosine, thymine, or their equivalents.
Sequencing the nucleic acid strand may comprise using the at least one line to detect the characteristic of the first magnetic sensor, the characteristic indicating presence or absence of the first cleavable magnetic label. The characteristic may be, for example, a magnetic field or a resistance, a frequency of a signal associated with or generated by a magnetic oscillator, a noise level, or a change in magnetic field or a change in resistance. The characteristic may result from a change in magnetic field or a change in resistance.
The method may also include a step of amplifying the at least one nucleic acid strand. If done, the amplification step may be done before or after binding the at least one nucleic acid strand to the first binding area. As a result of the amplifying, one or more amplicons may be bound to the first binding area.
In some embodiments, in response to a determination that the characteristic indicates the presence of the one or more magnetic nanoparticles coupled to the first binding area, a complementary base of the first nucleotide precursor is recorded in a record of a nucleic acid sequence of the nucleic acid strand.
In some embodiments, the first nucleotide precursor is nonextendable by the nucleic acid polymerase, and the method further comprises after detecting the characteristic, removing the first cleavable magnetic label and rendering the first nucleotide precursor extendable by the nucleic acid polymerase. In some embodiments, the first nucleotide precursor is not extendable by the nucleic acid polymerase. The first nucleotide precursor may be rendered extendable by chemical cleavage.
After sequencing the nucleic acid strand, the cleavable magnetic label may be removed by enzymatic or chemical cleavage.
In some embodiments, the first cleavable magnetic label has a first magnetic property, and the method further comprises, in the one or more rounds of addition, adding, to the first binding area, a second nucleotide precursor labeled by a second cleavable magnetic label having a second magnetic property. In some such embodiments, the method further comprises, in the one or more rounds of addition, adding, to the first binding area, a third nucleotide precursor labeled by a third cleavable magnetic label having a third magnetic property, and a fourth nucleotide precursor labeled by a fourth cleavable magnetic label having a fourth magnetic property.
In some embodiments, binding the at least one nucleic acid strand to the first binding area comprises attaching an adapter to an end of a respective one of the at least one nucleic acid strand, and coupling an oligonucleotide to the first binding area, wherein the oligonucleotide is capable of hybridizing to the adapter. In some embodiments, binding the at least one nucleic acid strand to the first binding area comprises covalently bonding each of the at least one nucleic acid strand to the first binding area. In some embodiments, binding the at least one nucleic acid strand to the first binding area comprises immobilizing the at least one nucleic acid strand via irreversible passive adsorption or affinity between molecules. In some embodiments, the first binding area comprises a cavity or a ridge, and binding the at least one nucleic acid strand to the first binding area comprises applying a hydrogel to the cavity or to the ridge.
In some embodiments, the nucleic acid polymerase is a Type B polymerase lacking 3′-5′ exonuclease activity. In some embodiments, the nucleic acid polymerase is a thermostable polymerase.
In some embodiments, using the at least one line comprises applying a current to the at least one line.
Methods for nucleic acid sequencing described herein rely on the use of magnetically-labeled nucleotide precursors comprising cleavable magnetic labels. These cleavable magnetic labels may comprise, for example, a magnetic nanoparticle, such as, for example, a molecule, a superparamagnetic nanoparticle, or a ferromagnetic particle. The magnetic labels may be nanoparticles with high magnetic anisotropy. Examples of nanoparticles with high magnetic anisotropy include, but are not limited to, Fe3O4, FePt, FePd, and CoPt. To facilitate chemical binding to nucleotides, the particles may be synthesized and coated with SiO2. See, e.g., M. Aslam, L. Fu, S. Li, and V. P. Dravid, “Silica encapsulation and magnetic properties of FePt nanoparticles,” Journal of Colloid and Interface Science, Volume 290, Issue 2, 15 Oct. 2005, pp. 444-449. Because magnetic labels of this size have permanent magnetic moments, the directions of which fluctuate randomly on very short time scales, some embodiments, described further below, rely on sensitive sensing schemes that detect fluctuations in magnetic field caused by the presence of the magnetic labels.
There are a number of ways to attach the magnetic labels to nucleotide precursors and to cleave the magnetic labels after incorporation of the nucleotide precursor. For example, the magnetic labels may be attached to a base, in which case they may be cleaved chemically. As another example, the magnetic labels may be attached to a phosphate, in which case they may be cleaved by polymerase or, if attached via a linker, by cleaving the linker.
In some embodiments, the magnetic label is linked to the nitrogenous base (A, C, T, G, or a derivative) of the nucleotide precursor. After incorporation of the nucleotide precursor and the detection by a sequencing device (e.g., as described in further detail below), the magnetic label is cleaved from the incorporated nucleotide.
In some embodiments, the magnetic label is attached via a cleavable linker. Cleavable linkers are known in the art and have been described, e.g., in U.S. Pat. Nos. 7,057,026, 7,414,116 and continuations and improvements thereof. In some embodiments, the magnetic label is attached to the 5-position in pyrimidines or the 7-position in purines via a linker comprising an allyl or azido group. In other embodiments, the linker comprises a disulfide, indole or a Sieber group. The linker may further contain one or more substituents selected from alkyl (C1-6) or alkoxy (C1-6), nitro, cyano, fluoro groups or groups with similar properties. Briefly, the linker can be cleaved by water-soluble phosphines or phosphine-based transition metal-containing catalysts. Other linkers and linker cleavage mechanisms are known in the art. For example, linkers comprising trityl, p-alkoxybenzyl esters and p-alkoxybenzyl amides and tert-butyloxycarbonyl (Boc) groups and the acetal system can be cleaved under acidic conditions by a proton-releasing cleavage agent. A thioacetal or other sulfur-containing linker can be cleaved using a thiophilic metals, such as nickel, silver or mercury. The cleavage protecting groups can also be considered for the preparation of suitable linker molecules. Ester- and disulfide containing linkers can be cleaved under reductive conditions. Linkers containing triisopropyl silane (TIPS) or t-butyldimethyl silane (TBDMS) can be cleaved in the presence of F ions. Photocleavable linkers cleaved by a wavelength that does not affect other components of the reaction mixture include linkers comprising O-nitrobenzyl groups. Linkers comprising benzyloxycarbonyl groups can be cleaved by Pd-based catalysts.
In some embodiments, the nucleotide precursor comprises a label attached to a polyphosphate moiety as described in, e.g., U.S. Pat. Nos. 7,405,281 and 8,058,031. Briefly, the nucleotide precursor comprises a nucleoside moiety and a chain of 3 or more phosphate groups where one or more of the oxygen atoms are optionally substituted, e.g., with S. The label may be attached to the α, β, γ or higher phosphate group (if present) directly or via a linker. In some embodiments, the label is attached to a phosphate group via a non-covalent linker as described, e.g., in U.S. Pat. No. 8,252,910. In some embodiments, the linker is a hydrocarbon selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl; see, e.g., U.S. Pat. No. 8,367,813. The linker may also comprise a nucleic acid strand; see, e.g., U.S. Pat. No. 9,464,107.
In embodiments in which the magnetic label is linked to a phosphate group, the nucleotide precursor is incorporated into the nascent chain by the nucleic acid polymerase, which also cleaves and releases the detectable magnetic label. In some embodiments, the magnetic label is removed by cleaving the linker, e.g., as described in U.S. Pat. No. 9,587,275.
In some embodiments, the nucleotide precursors are non-extendable “terminator” nucleotides, i.e., the nucleotides that have a 3′-end blocked from addition of the next nucleotide by a blocking “terminator” group. The blocking groups are reversible terminators that can be removed in order to continue the strand synthesis process as described herein. Attaching removable blocking groups to nucleotide precursors is known in the art. See, e.g., U.S. Pat. Nos. 7,541,444, 8,071,739 and continuations and improvements thereof. Briefly, the blocking group may comprise an allyl group that can be cleaved by reacting in aqueous solution with a metal-allyl complex in the presence of phosphine or nitrogen-phosphine ligands. Other examples of reversible terminator nucleotides used in sequencing by synthesis include the modified nucleotides described in International Application No. PCT/US2019/066670, filed Dec. 16, 2019 and entitled “3′-protected Nucleotides,” published on Jun. 25, 2020 as WO/2020/131759, which is hereby incorporated by reference in its entirety for all purposes.
Embodiments disclosed herein use magnetic sensors to detect the presence of magnetic labels coupled to nucleotide precursors as, for example, described above.
As shown in
Note that although the example discussed immediately above described the use of ferromagnets that have their moments oriented in the plane of the film at 90 degrees with respect to one another, a perpendicular configuration can alternatively be achieved by orienting the moment of one of the ferromagnetic layers 106A, 106B out of the plane of the film, which may be accomplished using what is referred to as perpendicular magnetic anisotropy (PMA).
In some embodiments, the magnetic sensors 105 use a quantum mechanical effect known as spin transfer torque. In such devices, the electrical current passing through one ferromagnetic layer 106A (or 106B) in a SV or a MTJ preferentially allows electrons with spin parallel to the layer's moment to transmit through, while electrons with spin antiparallel are more likely to be reflected. In this manner, the electrical current becomes spin polarized, with more electrons of one spin type than the other. This spin-polarized current then interacts with the second ferromagnetic layer 106B (or 106A), exerting a torque on the layer's moment. This torque can in different circumstances either cause the moment of the second ferromagnetic layer 106B (or 106A) to precess around the effective magnetic field acting upon the ferromagnet, or it can cause the moment to reversibly switch between two orientations defined by a uniaxial anisotropy induced in the system. The resulting spin torque oscillators (STOs) are frequency-tunable by changing the magnetic field acting upon them. Thus, they have the capability to act as magnetic-field-to-frequency (or phase) transducers, as is shown in
The magnetic sensors 105 and portions of the lines 120 within the magnetic sensor array 110 are illustrated using dashed lines to indicate that they might not be visible in the top view of the apparatus 100. As explained in further detail below, the magnetic sensors 105 are embedded in the apparatus 100 and are protected from the contents of the binding areas 115 (e.g., by an insulator). Accordingly, it is to be understood that the various illustrated components (e.g., lines 120, magnetic sensors 105, etc.) might not be visible in a physical instantiation of the apparatus 100 (e.g., they may be embedded in or covered by protective material, such as an insulator).
In some embodiments, each of the magnetic sensors 105 of the magnetic sensor array 110 is a thin film device that uses the magnetoresistance (MR) effect to detect magnetic labels in an associated binding area 115, described in further detail below. As described in more detail below, each magnetic sensor 105 may operate as a potentiometer with a resistance that varies as the strength and/or direction of the sensed magnetic field changes.
The exemplary magnetic sensor array 110 in the exemplary embodiment of
Referring now to
As shown in the exemplary embodiment of
The binding areas 115 hold fluids. The magnetic sensors 105 are able to detect magnetic labels (e.g., nanoparticles) that are in the binding areas 115. Thus, in some embodiments the surface 116 of each binding area 115 has properties and characteristics that protect the magnetic sensors 105 from whatever fluids are in the binding areas 115, while still allowing the magnetic sensors 105 to detect magnetic labels that are within the binding areas 115. The material of the surface 116 (and possibly of the rest of the binding area 115) may be or comprise an insulator. For example, in some embodiments, the surface 116 comprises polypropylene, gold, glass, or silicon. It is to be understood that the surface 116 may be the exposed surface of a multi-layer structure disposed over the line(s) 120 that reside over the magnetic sensors 105. For example, in embodiments in which the surface 116 comprises a conductor (e.g., gold), a layer of an insulating material can be used to separate the conductor from the line(s) 120 over the magnetic sensors 105. (See
In some embodiments, the surface 116 of a binding area 115 has a structure (or multiple structures) configured to anchor nucleic acid to the surface 116. For example, the structure (or structures) may include a cavity or a ridge. Furthermore, in some embodiments, the surface 116 has characteristics that promote amplification of nucleic acids. For example, the apparatus 100 may facilitate bridge amplification to promote the generation of clonal clusters of a single nucleic acid strand within each of the binding areas 115.
Each binding area 115 shown in the exemplary embodiment of
In some embodiments, such as the exemplary embodiment illustrated in
Each of the lines 120 in the exemplary embodiment of
In some embodiments, some or all of the binding areas 115 reside in trenches in the lines 120 passing over the magnetic sensors 105. For example, as shown in
To simplify the explanation,
In some embodiments, the sensing circuitry 130 detects deviations or fluctuations in the magnetic environment of some or all of the magnetic sensors 105 in the magnetic sensor array 110. For example, a magnetic sensor 105 of the MR type in the absence of a magnetic label should have relatively small noise above a certain frequency as compared to a magnetic sensor 105 in the presence of a magnetic label, because the field fluctuations from the magnetic label will cause fluctuations of the moment of the sensing ferromagnet. These fluctuations can be measured using heterodyne detection (e.g., by measuring noise power density) or by directly measuring the voltage of the magnetic sensor 105 and evaluated using a comparator circuit to compare to a dummy sensor element that does not sense the binding area 115. In the case the magnetic sensors 105 include STO elements, fluctuating magnetic fields from magnetic labels would cause jumps in phase for the magnetic sensors due to instantaneous changes in frequency, which can be detected using a phase detection circuit. Another option is to design the STO such that it oscillates only within a small magnetic field range such that the presence of a magnetic label would turn off the oscillations. It is to be understood that the examples provided above are merely exemplary. Other detection methodologies are contemplated and are within the scope of this disclosure.
In some embodiments, the magnetic sensor array 110 includes a selector element that reduces the chances of “sneak” currents that could transmit through neighboring elements and degrade the performance of the magnetic sensor array 110.
In
In some embodiments, use of the apparatus 100 allows for amplification of nucleic acid, such as, for example, using bridge amplification (discussed further below). The distances between the individual strands in the clonal clusters created through an amplification procedure, such as described below in more detail, can be estimated to select the size(s) and density of magnetic sensors 105 in the magnetic sensor array 110. For example, to estimate the distances, one can consider both the contour length (e.g., the length of a straightened-out strand of DNA) and the persistence length (e.g., the average length of a strand after it bends over during a bridge amplification procedure) of a 200 base pair (BP) double-stranded DNA, chosen because the average strand length for many nucleic acid sequencing applications is 200 BP, and double-stranded DNA is less flexible than single-stranded DNA and therefore provides an upper bound. The average contour length is about 65 nm, and the persistence length is approximately 35 nm (see, e.g., S. Brinkers et al., “The persistence length of double stranded DNA determined using dark field tethered particle motion,” J. Chem. Phys. (2009) 130:215105). Because the DNA bends over during the bridge amplification process, the average distance between amplified clones should be somewhere between the contour length and the persistence length. Accordingly, that distance can be estimated to be approximately 40 nm. Assuming that, from a signal-to-noise ratio (SNR) perspective, it may be desirable to have between tens and hundreds of copied strands to sequence each originally-attached target strand, the magnetic sensors 105 can have dimensions on the order of, for example, approximately 10 nm to approximately 1 μm. It is to be appreciated that because the sequencing uses magnetic nanoparticles and not fluorescence, the spacing between adjacent magnetic sensors 105 can be much smaller than that required for optical system, which are limited by diffraction effects. For example, in embodiments of the apparatus 100 disclosed herein, adjacent magnetic sensors 105 may be between approximately 20 nm and approximately 30 nm apart.
In some embodiments, the apparatus 100 is fabricated using photolithographic processes and thin film deposition.
Optionally, at 156, insulating material may be deposited over the at least one line 120, and then, also optionally, at 158, the at least one line 120 can be uncovered. For example, the at least one line 120 can be uncovered using chemical mechanical polishing (CMP).
At 160, a plurality of magnetic sensors 105 (e.g., the magnetic sensor array 110) is fabricated on the at least one line 120. The plurality of magnetic sensors 105 may be fabricated, for example, by depositing a plurality of layers on the at least one line 120, and then patterning the plurality of layers to form the plurality of magnetic sensors 105. The plurality of layers may be deposited using any suitable technique. For example, the plurality of layers may be deposited by depositing a first ferromagnetic layer (e.g., the layer 106B shown in
In some embodiments, each magnetic sensor 105 of the magnetic sensor array 110 has a bottom surface 108 and a top surface 109. (See, e.g.,
In some embodiments, each of the plurality of magnetic sensors 105 has a predetermined shape, which may be the same for all magnetic sensors 105 of the plurality of magnetic sensors 105 or different for two or more magnetic sensors 105. The predetermined shape may be any suitable shape, including, for example, substantially cylindrical or substantially cuboid. A lateral dimension of each of the plurality of magnetic sensors 105 may be, for example, between approximately 10 nm and approximately 1 μm. As used herein, the term “lateral dimension” means a dimension in the x-y plane shown in
Referring again to the method embodiment of
Optionally, at 164, a chemical mechanical polishing step may be performed to expose the top surface 109 of each of the plurality of magnetic sensors 105.
At 166, at least one additional line 120 is fabricated using any suitable technique. For example, the at least one additional line 120 may be fabricated by depositing a layer of metal, performing photolithography to define the at least one additional line 120, and removing a portion of the layer of metal, thereby leaving the at least one additional line 120.
In some embodiments, each of the at least one additional line 120 is coupled to the top surface 109 of at least one magnetic sensor 105 in the magnetic sensor array 110. In some embodiments, the top surface 109 of each magnetic sensor 105 is in contact with the same line 120. In some embodiments, the bottom surface 108 of a magnetic sensor 105 is in contact with a first line 120A, and the top surface 109 of the magnetic sensor 105 is in contact with a second line 120B.
In some embodiments, the plurality of magnetic sensors 105 is in a rectangular magnetic sensor array 110. In such embodiments, the at least one line 120 (e.g., the first or bottom line 120) may correspond to one or more rows of the rectangular array, and the at least one additional line 120 (e.g., the second or top line 120) may correspond to one or more columns of the rectangular array, or vice versa.
At 168, a plurality of binding areas 115 is created using any suitable technique. For example, the plurality of binding areas 115 may be created by applying a mask over the regions corresponding to the plurality of binding areas 115, depositing a metal layer over the mask, and lifting the mask. For example, photolithography may be performed to define a mask with windows in polymer overlapping the top lines 120, except immediately above the magnetic sensors 105. A subsequent metal deposition and lift-off may then be performed to thicken the top lines 120 away from the magnetic sensors 105, which creates a shallow trench above each magnetic sensor 105 and reduces the resistance of the top lines 120 to improve noise performance. These shallow trenches can define the binding areas 115.
Accordingly, in some embodiments, the plurality of binding areas 115 is created by making a trench in a top line 120 at a position corresponding to the top of a magnetic sensor 105, and then depositing insulating material over the trench. For example, in embodiments in which the plurality of magnetic sensors 105 is arranged in a rectangular array 110, with some lines 120 (the bottom lines 120) below the magnetic sensors 105 and other lines 120 (the top lines 120) above the magnetic sensors 105, a trench may be etched in each of the top lines 120 at the locations where they pass over the magnetic sensors 105. The binding areas 115 are then defined by the trenches above the magnetic sensors 105 (e.g., as shown in
In some embodiments, after creating the binding areas 115 (e.g., after lifting the mask and/or creating the trenches described above), a thin layer of additional insulating material (e.g., an oxide such as SiO2 or a nitride) is deposited (e.g., using atomic layer deposition) over the plurality of additional lines 120 and the plurality of binding areas 115. The thickness of the additional insulating material may be, for example, between approximately 3 nm and approximately 20 nm. Any suitable insulating material that electrically isolates the magnetic sensors 105 from magnetic labels in the binding areas 115 and protects the magnetic sensors 105 from fluids expected to be added to the binding areas 115 may be used for this purpose. For example, the additional insulating material may comprise silicon dioxide (SiO2), aluminum oxide (AlOx), or silicon nitride (SiN), or the like.
At 170, the method 150 ends.
In some embodiments, nucleic acid is sequenced using immobilized nucleic acid strands (potentially in clonal clusters) that are tethered to the apparatus 100 in the proximity of the magnetic sensors 105 of the magnetic sensor array 110. Four types of reversible terminator bases (RT-bases) may then be added, either together or one at a time, and non-incorporated nucleotides are washed away. Then the magnetic labels, along with the terminal 3′ blocker, may be chemically removed from the nucleic acid strands before the next sequencing cycle begins.
The nucleic acid strands can be prepared in any suitable manner. For example, the nucleic acid strands can be prepared by random fragmentation of a nucleic acid sample, followed by 5′and 3′ adapter ligation. These strands of the nucleic acid may then be captured on oligos bound or attached to the surfaces 116 of at least some of the binding areas 115. Linear or exponential amplification including bridge amplification may be used to amplify the strands prior to sequencing.
Bridge amplification and other amplification techniques are well known in the art and can be used with the apparatus 100 in accordance with some embodiments. To begin bridge amplification, the nucleic acid to be sequenced can be attached to a substrate using, for example, adapter strands that are, for example, immobilized in a hydrogel. Then polymerase, primers, and nucleotide precursors may be introduced into the binding area 115 to create double-stranded nucleic acids from the single target strands. Next, the double strands are denatured, which separates the double-sided nucleic acid strands into two single strands that are complements of each other. Bridge formation involves chemistry to cause the single strands to fold over and attach to the complementary adapter strands immobilized on the substrate as shown. Once again, polymerase, primers, and nucleotide precursors are introduced into the binding area 115 to convert individual single strand “bridges” into double-sided strands. Following this step, the double strands are denatured to produce complementary single strands, one being the original “forward” strand and the other a copied “reverse” strand. After repeating these steps many times, clonal clusters are formed with both forward and reverse copies. One of the two clusters (e.g., the reverse strands) can then be cleaved from the binding area 115 before sequencing the remaining cluster (e.g., the forward strands).
The use of an amplification procedure in connection with the apparatus 100 for nucleic acid sequencing can improve the SNR of the sequencing process and thereby improve accuracy of the sequencing. The SNR improvement results because the presence of many copies of the same nucleic acid strand to be sequenced within a binding area 115 allows a larger number of magnetically-labeled nucleotide precursors to be incorporated within the binding area 115. The incorporation of a larger number of magnetically-labeled nucleotide precursors, in turn, increases the likelihood that the magnetic sensor 105 associated with that binding area 115 will detect the presence of the magnetic labels within the binding area 115. Thus, having a larger number of copies of the strand to be sequenced reduces the likelihood that the magnetic sensor 105 will miss the incorporation of a magnetically-labeled nucleotide precursor and thereby make a sequencing error.
To sequence the nucleic acid strands, magnetically-labeled nucleotide precursors may be introduced one at a time or all at once, as described below.
In some embodiments, magnetically-labeled nucleotide precursors are introduced one at a time. In such embodiments, the same magnetic label can be used for all of the nucleotide precursors. It is to be understood that as used herein, the phrase “the same magnetic label” does not refer to the same physical instance of a single magnetic label (i.e., it does not mean that a particular instance of a physical label is reused); instead, it refers to multiple physical instantiations of magnetic labels, all of which have identical characteristics or properties that render individual instances of them indistinguishable from one another. In contrast, the phrase “different magnetic labels” refers to magnetic labels that, either individually or as a group, have different characteristics or properties that allow them to be distinguished from other magnetic labels, whether individually or as a group.
In some embodiments, the nucleic acid strands are extended one nucleotide at a time, and the magnetic sensor array 110 is used to identify the bound magnetically-labeled nucleotide precursors.
At optional step 206, the nucleic acid strand(s) may be amplified using any suitable method, such as, for example, by leveraging the polymerase chain reaction (PCR) or linear amplification.
At 208, an extendible primer is added to the binding area 115.
At 210, a nucleic acid polymerase is added to the binding area 115. The nucleic acid polymerase may be any suitable nucleic acid polymerase. Desired characteristics of a nucleic acid polymerase (such as a DNA polymerase) that finds use in nucleic acid sequencing include one or more of the following: fast association rate for nucleic acid template and for nucleotide precursors or slow dissociation rate for nucleic acid template and for nucleotide precursors (association and dissociation rates being kinetic characteristics of a nucleic acid polymerase under a defined set of reaction conditions); high fidelity, low or undetectable exonuclease activity, including low or undetectable 3′-5′ exonuclease (proofreading) activity or low or undetectable 5′-3′ exonuclease activity; effective DNA strand displacement, high stability, high processivity (including long read length), salt tolerance and ability to incorporate modified nucleotide precursors including the precursors described herein.
Some examples of a suitable polymerase include B-family (Type B) polymerases lacking the 3′-5′ exonuclease activity.
In some embodiments, the polymerase is a thermostable polymerase. Thermostable nucleic acid polymerases include Thermus aquaticus Taq DNA polymerase, Thermus sp. Z05 polymerase, Thermus flavus polymerase, Thermotoga maritima polymerases, such as TMA-25 and TMA-30 polymerases, Tth DNA polymerase, Pyrococcus furiosus (Pfu), Pyrococcus woesei (Pwo), Thermatoga maritima (Tma) and Thermococcus Litoralis (Tli or Vent) and the like.
In some embodiments, the polymerase lacks detectable 5′-3′ exonuclease activity. Examples of DNA polymerases substantially lacking 5′ to 3′ nuclease activity include the Klenow fragment of E. coli DNA polymerase I; a Thermus aquaticus DNA polymerase (Taq) lacking the N-terminal 235 amino acids (“Stoffel fragment”), See U.S. Pat. No. 5,616,494. Other examples include a thermostable DNA polymerase having sufficient deletions (e.g., N-terminal deletions), mutations, or modifications so as to eliminate or inactivate the domain responsible for the 5′-3′ nuclease activity. See, e.g., U.S. Pat. No. 5,795,762.
In some embodiments, the polymerase lacks detectable 3′-5′ exonuclease activity. Examples of DNA polymerases substantially lacking the 3′-5′ exonuclease activity include the Taq polymerase and its derivatives and any B-family (Type B) polymerase with naturally occurring or engineered deletion of the proofreading domain.
In some embodiments, the polymerase has been modified or engineered to enable or enhance incorporation of nucleotide analogs such as 3′-modified nucleotides; see, e.g., U.S. Pat. Nos. 10,150,454, 9,677,057, and 9,273,352.
In some embodiments, the polymerase has been modified or engineered to enable or enhance incorporation of nucleotide analogs such as 5′-phosphate-modified nucleotides; see, e.g., U.S. Pat. Nos. 10,167,455 and 8,999,676. In some embodiments, such polymerases are phi29 derived polymerases; see, e.g., U.S. Pat. Nos. 8,257,954 and 8,420,366. In some embodiments, such polymerases are phiCPV4 derived polymerases; see, e.g., U.S. Patent Publication No. US20180245147.
In some embodiments, the polymerase is modified or engineered by selection to successfully incorporate a desired modified nucleotide or to incorporate nucleotides and nucleotide analogs with desired accuracy and processivity. Methods of selecting such modified polymerases are known in the art; see, e.g., U.S. Patent Publication No. US20180312904A1, entitled “Polymerase Compositions and Methods of Making and Using Same.”
It is to be understood that steps 208 and 210 may be combined or their order reversed.
Optionally, at 212, the binding area 115 may be washed before adding the magnetically-labeled nucleotide precursor at step 214.
At 228, a magnetically-labeled nucleotide precursor is selected for the sequencing cycle. In some embodiments, the magnetically-labeled nucleotide precursor is selected from adenine, guanine, cytosine, thymine, or their equivalents. In some embodiments, the magnetically-labeled nucleotide precursor comprises one of magnetically-labeled dATP, dGTP, dCTP, dTTP, or equivalents. The magnetically-labeled nucleotide precursor may be labeled conventional, natural, unconventional, or an analog nucleotide. The term “conventional” or “natural” when referring nucleotide precursors refers to those occurring naturally (i.e., for DNA these are dATP, dGTP, dCTP and dTTP). The term “unconventional” or “analog” when referring to nucleotide precursors includes modifications or analogues of conventional bases, sugar moieties, or inter-nucleotide linkages in nucleotide precursors. For example, dITP, 7-deaza-dGTP, 7-deaza-dATP, alkyl-pyrimidine nucleotides (including propynyl dUTP) are examples of nucleotides with unconventional bases. Some unconventional sugar modifications include modifications at the 2′-position. For example, ribonucleotides with 2′-OH (i.e., ATP, GTP, CTP, UTP) are unconventional nucleotides for a DNA polymerase. Other sugar analogs and modifications include D-ribosyl, 2′ or 3′ D-deoxyribosyl, 2′,3′-D-dideoxyribosyl, 2′,3′-D-didehydrodideoxyribosyl, 2′ or 3′ alkoxyribosyl, 2′ or 3′ aminoribosyl, 2′ or 3′ mercaptoribosyl, 2′ or 3′ alkothioribosyl, acyclic, carbocyclic or other modified sugar moieties. Additional examples include 2′-PO4 analogs, which are terminator nucleotides. (See, e.g., U.S. Pat. No. 7,947,817 or other examples described herein). Unconventional linkage nucleotides include phosphorothioate dNTPs ([α-S]dNTPs), 5′-[α-borano]-dNTPs and [α]-methyl-phosphonate dNTPs.
At 214, the selected magnetically-labeled nucleotide precursor is added to the binding area 115.
At 216, sequencing is performed to determine whether the selected magnetically-labeled nucleotide precursor has bound to the polymerase or has been incorporated into the extendable primer. The sequencing step 216 can include multiple sub-steps, as shown in
At decision point 220, it is determined whether the detection result indicates that the magnetically-labeled nucleotide precursor has bound to the polymerase or has been incorporated into the extendable primer. For example, the determination may be based on the presence or absence of the characteristic, e.g., if the characteristic is detected, the magnetically-labeled nucleotide precursor is deemed to have bound to the polymerase or to have been incorporated into the extendable primer, and if the characteristic is not detected, the magnetically-labeled nucleotide precursor is deemed not to have bound to the polymerase or have been incorporated into the extendable primer. As another example, the determination may be based on a magnitude or value of the characteristic, e.g., if the magnitude or value is within a specified range, the magnetically-labeled nucleotide precursor is deemed to have bound to the polymerase or have been incorporated into the extendable primer, and if the magnitude or value is not within the specified range, the magnetically-labeled nucleotide precursor is deemed not to have bound to the polymerase or have been incorporated into the extendable primer.
The detection (sub-step 218) and determination (decision point 220) may use or rely on all or fewer than all of the magnetic sensors 105 in the magnetic sensor array 110. The determination of whether the characteristic is present or absent, or the value of the characteristic (decision point 220), may be based on aggregating, averaging, or otherwise processing the detection results (sub-step 218) from some or all of the magnetic sensors 105 in the magnetic sensor array 110.
If, at decision point 220, it is determined that the magnetically-labeled nucleotide precursor has bound to the polymerase or has been incorporated into the extendable primer, then at step 222, an indication of a complementary base of the magnetically-labeled nucleotide precursor is recorded in a record of the nucleic acid sequence of the nucleic acid strand.
In some embodiments, the magnetically-labeled nucleotide precursor is nonextendable by the nucleic acid polymerase, and, therefore, after detecting the characteristic, the magnetic label must be removed to render the magnetically-labeled nucleotide precursor extendable by the nucleic acid polymerase. In some embodiments, a moiety of the first magnetically-labeled nucleotide precursor is not extendable by the nucleic acid polymerase, and the moiety of the first magnetically-labeled nucleotide precursor is rendered extendable by chemical cleavage. As illustrated in
After the magnetic label has been removed at 226, another magnetically-labeled nucleotide precursor is selected at 228. The newly-selected magnetically-labeled nucleotide precursor, which may be the same as or different from the one used in the just-completed cycle, is then added to the binding area 115 at step 214, and the sequencing step 216 is performed again to determine whether the newly-selected magnetically-labeled nucleotide precursor has bound to the polymerase or has been incorporated into the extendible primer.
If, at decision point 220, it is determined that the magnetically-labeled nucleotide precursor has not bound to the polymerase and has not been incorporated into the extendable primer, the method moves to step 228, where another magnetically-labeled nucleotide precursor is selected. In this case, because the previously-tried magnetically-labeled nucleotide precursor was not a match, the selected magnetically-labeled nucleotide precursor should be different from the one used in the just-completed cycle.
Although
It is to be understood that after some number of sequencing cycles, it may be desirable or necessary to perform step 210 to add additional molecules of the nucleic acid polymerase to the binding area(s) 115 to replenish the polymerase.
At 252, the method 250 begins. Steps 254, 256, 258, 260, and 262 are the same as steps 204, 206, 208, 210, and 212 shown and described in the context of
At step 264, up to four magnetically-labeled nucleotide precursors are added to the binding area(s) 115 of the apparatus 100. Each of the added magnetically-labeled nucleotide precursors is labeled with a different magnetic label so that the magnetic sensors 105 can distinguish between the different magnetically-labeled nucleotide precursors. Specifically, each of the magnetic labels has a different and distinguishable magnetic property (e.g., a first magnetic label used for the first magnetically-labeled nucleotide precursor has a first magnetic property, the second magnetic label used for the second magnetically-labeled nucleotide precursor has a second magnetic property, etc.).
At 266, sequencing is performed to determine which of the added magnetically-labeled nucleotide precursors has bound to the polymerase or incorporated into the extendable primer. The sequencing step 266 can include multiple sub-steps, as shown in
At decision point 270, it is determined whether a first magnetic property has been detected, where the first magnetic property indicates that the first magnetically-labeled nucleotide precursor has bound to the polymerase or has been incorporated into the extendable primer. The determination may be based, for example, on the presence or absence of the first magnetic property, e.g., if the first magnetic property is detected, the first magnetically-labeled nucleotide precursor is deemed to have bound to the polymerase or have incorporated into the extendable primer, and if the first magnetic property is not detected, the first magnetically-labeled nucleotide precursor is deemed not to have bound to the polymerase or incorporated into the extendable primer. As another example, the determination may be based on a magnitude or value of the first magnetic property, e.g., if the magnitude or value is within a specified range, the first magnetically-labeled nucleotide precursor is deemed to have bound to the polymerase or incorporated into the extendable primer, and if the magnitude or value is not within the specified range, the first magnetically-labeled nucleotide precursor is deemed not to have bound to the polymerase or incorporated into the extendable primer.
If it is determined at decision point 270 that the first magnetic property has been detected, the method moves to step 278, where a complementary based of the first magnetically-labeled nucleotide precursor is recorded in a record of the nucleic acid sequence of the nucleic acid strand.
If, at decision point 270, it is determined that the first magnetic property has not been detected, the method 250 moves to decision point 272, at which it is determined whether a second magnetic property has been detected, where the second magnetic property indicates that the second magnetically-labeled nucleotide precursor has bound to the polymerase or incorporated into the extendable primer. The determination may be made in any the ways described above for the determination of the first magnetic property. If it is determined at decision point 272 that the second magnetic property has been detected, the method moves to step 278, where a complementary based of the second magnetically-labeled nucleotide precursor is recorded in a record of the nucleic acid sequence of the nucleic acid strand.
If, at decision point 272, it is determined that the second magnetic property has not been detected, the method 250 moves to decision point 274, at which it is determined whether a third magnetic property has been detected, where the third magnetic property indicates that the third magnetically-labeled nucleotide precursor has bound to the polymerase or incorporated into the extendable primer. The determination may be made in any the ways described above for the determination of the first magnetic property. If it is determined at decision point 274 that the third magnetic property has been detected, the method moves to step 278, where a complementary based of the third magnetically-labeled nucleotide precursor is recorded in a record of the nucleic acid sequence of the nucleic acid strand.
Finally, if, at decision point 274, it is determined that the third magnetic property has not been detected, the method 250 moves to decision point 276, at which it is determined whether a fourth magnetic property has been detected, where the fourth magnetic property indicates that the fourth magnetically-labeled nucleotide precursor has bound to the polymerase or incorporated into the extendable primer. The determination may be made in any the ways described above for the determination of the first magnetic property. If it is determined at decision point 276 that the fourth magnetic property has been detected, the method moves to step 278, where a complementary based of the third magnetically-labeled nucleotide precursor is recorded in a record of the nucleic acid sequence of the nucleic acid strand. If, at decision point 276, it is determined that the fourth magnetic property has not been detected, the method 250 moves back to step 264.
The detection (sub-step 268) and determinations (decision points 270, 272, 274, and 276) may use or rely on all or fewer than all of the magnetic sensors 105 in the magnetic sensor array 110. The determination of whether a particular magnetic property is present or absent, or the value of the characteristic, may be based on aggregating, averaging, or otherwise processing the detection results (sub-step 268) from some or all of the magnetic sensors 105 in the magnetic sensor array 110.
In the embodiment illustrated in
As explained above, in some embodiments, the magnetically-labeled nucleotide precursor is nonextendable by the nucleic acid polymerase, and, therefore, after detecting the characteristic, the magnetic label must be removed to render the magnetically-labeled nucleotide precursor extendable by the nucleic acid polymerase. In some embodiments, a moiety of the first magnetically-labeled nucleotide precursor is not extendable by the nucleic acid polymerase, and the moiety of the first magnetically-labeled nucleotide precursor is rendered extendable by chemical cleavage. In embodiments in which the magnetically-labeled nucleotide precursor is nonextendable by the nucleic acid polymerase, after the record of the nucleic acid sequence of the nucleic acid strand has, at step 278, been augmented (or begun), at decision point 280 it is determined whether additional sequencing cycles are to be performed. If so (the “No” branch of decision point 280), the magnetic label of the incorporated nucleotide precursor is removed. The magnetic label may be removed chemically, enzymatically, or by other means known in the art, and the method 250 proceeds to step 264, where up to four magnetically-labeled nucleotide precursors are added to the binding area 115 (potentially after performing a washing step similar or identical to the illustrated step 262). The sequencing step 266 is then performed again to identify the next magnetically-labeled nucleotide precursor to bind to the polymerase.
If, at decision point 280, it is determined that no additional sequencing cycles are to be performed (the “Yes” branch of decision point 280), the method 250 ends at 284.
In the foregoing description and in the accompanying drawings, specific terminology has been set forth to provide a thorough understanding of the disclosed embodiments. In some instances, the terminology or drawings may imply specific details that are not required to practice the invention.
To avoid obscuring the present disclosure unnecessarily, well-known components are shown in block diagram form and/or are not discussed in detail or, in some cases, at all.
Unless otherwise specifically defined herein, all terms are to be given their broadest possible interpretation, including meanings implied from the specification and drawings and meanings understood by those skilled in the art and/or as defined in dictionaries, treatises, etc. As set forth explicitly herein, some terms may not comport with their ordinary or customary meanings.
As used in the specification and the appended claims, the singular forms “a,” “an” and “the” do not exclude plural referents unless otherwise specified. The word “or” is to be interpreted as inclusive unless otherwise specified. Thus, the phrase “A or B” is to be interpreted as meaning all of the following: “both A and B,” “A but not B,” and “B but not A.” Any use of “and/or” herein does not mean that the word “or” alone connotes exclusivity.
As used in the specification and the appended claims, phrases of the form “at least one of A, B, and C,” “at least one of A, B, or C,” “one or more of A, B, or C,” and “one or more of A, B, and C” are interchangeable, and each encompasses all of the following meanings: “A only,” “B only,” “C only,” “A and B but not C,” “A and C but not B,” “B and C but not A,” and “all of A, B, and C.”
To the extent that the terms “include(s),” “having,” “has,” “with,” and variants thereof are used in the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising,” i.e., meaning “including but not limited to.” The terms “exemplary” and “embodiment” are used to express examples, not preferences or requirements. The term “coupled” is used herein to express a direct connection/attachment as well as a connection/attachment through one or more intervening elements or structures.
The terms “over,” “under,” “between,” and “on” are used herein refer to a relative position of one feature with respect to other features. For example, one feature disposed “over” or “under” another feature may be directly in contact with the other feature or may have intervening material. Moreover, one feature disposed “between” two features may be directly in contact with the two features or may have one or more intervening features or materials. In contrast, a first feature “on” a second feature is in contact with that second feature.
The terms “substantially” and “approximately” are used to describe a structure, configuration, dimension, etc. that is largely or nearly as stated, but, due to manufacturing tolerances and the like, may in practice result in a situation in which the structure, configuration, dimension, etc. is not always or necessarily precisely as stated. For example, describing two lengths as “substantially equal” or “approximately equal” means that the two lengths are the same for all practical purposes, but they may not (and need not) be precisely equal at sufficiently small scales. As another example, a structure that is “substantially vertical” or “approximately vertical” would be considered to be vertical for all practical purposes, even if it is not precisely at 90 degrees relative to horizontal.
The drawings are not necessarily to scale, and the dimensions, shapes, and sizes of the features may differ substantially from how they are depicted in the drawings.
Although specific embodiments have been disclosed, it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the disclosure. For example, features or aspects of any of the embodiments may be applied, at least where practicable, in combination with any other of the embodiments or in place of counterpart features or aspects thereof. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.
This application claims priority to, and hereby incorporates by reference in its entirety the contents of, U.S. provisional application No. 62/987,831, filed Mar. 10, 2020 and entitled “MAGNETIC SENSOR ARRAYS FOR NUCLEIC ACID SEQUENCING AND METHODS OF MAKING AND USING THEM” (Attorney Docket No. ROA-1001P-US/P35967-US).
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US21/21274 | 3/7/2021 | WO |
Number | Date | Country | |
---|---|---|---|
62987831 | Mar 2020 | US |